AI-generated research brief — verify at source
Pfizer’s rAAV9 Mini-Dystrophin Gene Therapy Fails Primary Efficacy Endpoint in Duchenne Trial
At 52 weeks, fordadistrogene movaparvovec produced no meaningful improvement over placebo in motor function scores among young boys with Duchenne muscular dystrophy, with the treatment and placebo groups showing nearly identical changes from baseline (difference of 0.09 points on the NSAA scale; 95% CI −1.46 to 1.64; p=0.91). The trial’s sponsor, Pfizer, has subsequently discontinued all further clinical development of this investigational gene therapy.
What Was Studied
This trial investigated whether fordadistrogene movaparvovec — a recombinant adeno-associated virus serotype 9 (rAAV9) vector engineered to deliver a functional mini-dystrophin transgene — could slow the progressive motor decline characteristic of Duchenne muscular dystrophy (DMD), a severe X-linked condition caused by mutations in the single gene encoding dystrophin. The study addressed a central question in the DMD field: whether viral gene transfer can produce clinically meaningful functional benefit in ambulatory children at an early stage of disease.
How It Was Studied
CIFFREO was a phase 3, double-blind, randomised, placebo-controlled trial conducted across 45 academic and hospital sites in 15 countries, including the USA, UK, France, Germany, Japan, and Australia. Eligible participants were ambulatory male patients aged 4 to under 8 years with a confirmed genetic diagnosis of DMD. A total of 122 participants were randomly assigned in a 2:1 ratio — 81 to receive a single intravenous infusion of fordadistrogene movaparvovec at a dose of 2 × 10¹⁴ vg/kg and 41 to receive placebo — with stratification by age group (under 6 years versus 6 years and older). The primary efficacy analysis was performed in 64 participants in the treatment group and 28 in the placebo group, with a follow-up period of 52 weeks. The primary endpoint was change from baseline in the North Star Ambulatory Assessment (NSAA) total score, a validated functional motor scale used widely in DMD research.
What Was Observed
- The primary efficacy endpoint was not met: the least squares mean change in NSAA total score from baseline to week 52 was 1.46 points in the treatment group and 1.37 points in the placebo group — a difference of just 0.09 points that was neither statistically significant nor clinically meaningful (95% CI −1.46 to 1.64; p=0.91). Both groups showed similar modest improvement, suggesting no functional benefit attributable to the gene therapy.
- The safety profile was substantially worse in the treatment group: adverse events occurred in 99% of treated participants compared with 77% of those on placebo. The most prominent treatment-emergent events were vomiting (76% vs. 14%), pyrexia (62% vs. 9%), decreased appetite (33% vs. 3%), and nausea (29% vs. 9%), consistent with an acute immune and inflammatory response to the viral vector.
- Serious adverse events were more than twice as frequent in the fordadistrogene movaparvovec group (32%) compared with the placebo group (14%), including elevated liver glutamate dehydrogenase in 24% of treated participants and none in the placebo group, signalling hepatic stress. There were no deaths in either group.
Why This Matters
This result is a significant setback for the rAAV9-based mini-dystrophin approach in DMD, adding to growing questions about whether truncated dystrophin constructs delivered via viral vectors can achieve sufficient functional restoration in a meaningful clinical window. The failure follows other mixed or limited outcomes in the broader DMD gene therapy pipeline and underscores how challenging it is to translate molecular expression data into functional motor benefit. The decision to discontinue development signals that the field must reexamine both transgene design and vector biology in this disease context.
How to Read This Result
While the trial was rigorously designed and internationally conducted, the primary analysis included fewer participants than originally enrolled, and the relatively short 52-week follow-up may not capture the full trajectory of functional change in a slowly progressive disease.
Limitations
The abstract does not explicitly report study limitations beyond the reduced primary analysis population size. The early termination of development means longer-term efficacy and durability data will not be available. Generalisability may also be constrained by the narrow age range and ambulatory status of enrolled participants.